Use App
Trending
News
Earnings
All
DIA
0.74%
SPY
0.99%
QQQ
1.50%
Trending
XRP
0.64%
CAG
1.31%
ETH
1.32%
NVTS
2.51%
TE
1.68%
FCEL
7.16%
CRVS
5.12%
KTOS
1.98%
NFLX
7.26%
BONK
6.05%
XRP
0.64%
CAG
1.31%
ETH
1.32%
NVTS
2.51%
TE
1.68%
FCEL
7.16%
CRVS
5.12%
KTOS
1.98%
NFLX
7.26%
BONK
6.05%
Feed
News
Sentiment
Earnings
Fundamentals
Info
home
Symbol
VERU
news
Exchange:
NASDAQ
·
Updated 07:31 PM EDT
VERU
Veru Inc
$2.41
$0.03
(1.28%)
Today
·
Closed $2.38
$0.03
(1.26%)
After Hours
1
9
,
0
7
3
1
9
,
0
7
3
Earnings
Aug 12
Mkt Cap
$38.2M
Vol
89,490.00
News
all
press releases
This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection?
Veru will evaluate enobosarm alongside Novo Nordisk’s Wegovy in the Phase 2b PLATEAU trial in older adults with obesity.
Stocktwits
Full Article
Share to Feed
More News
Earnings call transcript: Veru Inc Q2 2026 shows improved financials
Press Releases
Full Article
Veru (VERU) Q1 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
A Look Ahead: Veru's Earnings Forecast
read more...
Benzinga
Top Wall Street Forecasters Revamp Veru Expectations Ahead Of Q4 Earnings
read more...
Benzinga
Veru Announces Novel Modified-Release Oral Formulation for Enobosarm
VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.
Zacks
<
...
1
>
Advertisement
|
Remove ads.
Latest VERU News
View
This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection?
Stocktwits
Earnings call transcript: Veru Inc Q2 2026 shows improved financials
Press Releases
Veru (VERU) Q1 2026 Earnings Call Transcript
Nasdaq News: Markets
Loading...
Top Discussions
SPY
What do you think the S&P 500's ($SPY) return will be next week?
31
74
10.6K votes
SG
Sweetgreen ($SG) was not linked to the cyclospora outbreak - are you a buyer of the stock?
2
1
129 votes
NFLX
Netflix ($NFLX) is down sharply following Q2 earnings, hitting a fresh 52-week low. Are you buying the dip?
20
31
3.9K votes
Advertisement
|
Remove ads.
Advertisement
|
Remove ads.
Watchlist
Trending
News
Explore
Community
Profile